搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
MedPage Today on MSN
9 小时
FDA Expands Approval of RSV Vaccine Abrysvo to Include All At-Risk Adults
The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...
1 小时
首款!辉瑞疫苗再获FDA批准
▎药明康德内容团队编辑日前,辉瑞(Pfizer)宣布美国FDA已批准其呼吸道合胞病毒(RSV)疫苗Abrysvo(RSVpreF),用于预防18至59岁高风险个体因RSV引起的下呼吸道疾病(LRTD)。此前,该疫苗已获批用于60岁及以上的成人群体。根 ...
1 天
3项关于RSV疫苗/药物最新数据公布,涉及辉瑞Abrysvo、GSK Arexvy......
近日,在洛杉矶举行的2024年美国感染性疾病周(IDWeek)会议期间,默沙东和辉瑞分别展示了其针对呼吸道合胞病毒(RSV)的预防药物新数据,并宣称这些药物对预防感染及相关住院具有强大的保护效果。IDWeek是全球感染病学领域的顶级学术盛会,每年吸引 ...
阿思達克財經網
19 小时
辉瑞(PFE.US)RSV疫苗获FDA批准用于18-59岁年龄段人群接种
智通财经获悉,美国食品药品监督管理局 (FDA)已批准辉瑞公司 (PFE.US) 的呼吸道合胞病毒 ...
The American Journal of Managed Care
9 小时
FDA Approves Abrysvo RSV Vaccine for Adults at Increased Risk
Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.
Zacks.com on MSN
10 小时
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) ...
10 小时
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...
1 天
FDA批准辉瑞制药公司的RSV疫苗扩大使用范围至50岁以下成年人
纽约 - 辉瑞制药公司(NYSE: ...
FiercePharma
11 小时
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...
BioPharma Dive
10 小时
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...
BioSpace
12 小时
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.
Pharmaceutical Technology
10 小时
FDA expands Pfizer’s RSV vaccine label to include all high-risk adults
Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈